{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:15:49Z","timestamp":1788833749901,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To understand the status of therapeutic drug monitoring (TDM) in China Mainland, and thus lay down the foundation for further improvement in TDM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In the present study, a nationwide questionnaire survey was conducted, which was distributed and collected using a mobile\u2010based application. Clinicians, pharmacists, and clinical laboratory physicians belonging to different levels of public hospitals were involved as subjects\/objects. The contents of the survey included TDM implementation in their hospital and information regarding their opinions and suggestions on TDM work. Mann\u2013Whitney test was used to compare the difference between top tertiary hospitals and non\u2013top tertiary hospitals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 475 questionnaires were collected, 383 from top tertiary hospitals (3A hospitals) and 92 from non\u2013top tertiary hospitals (other than 3A hospitals). A total of 240 clinicians, TDM pharmacists, and clinical laboratory physicians were involved, with an effective rate of 50.5%. Top tertiary hospitals were associated with certain advantages, such as the number of TDM testing facilities, annual sample size, number of monitoring varieties, and interpretation rate of monitoring reports, compared with non\u2013top tertiary hospitals. In particular, \u03b2-lactamase inhibitor, olanzapine, carbamazepine, and glucocorticoids seemed to be the main projects that clinicians wanted to assess. The drugs for which TDM was commonly performed included vancomycin, valproic acid, carbamazepine, phenytoin sodium, and methotrexate. The most commonly used detection methods include high-performance liquid chromatography, immunization, 2D-LC, and LC-MS. The monitoring concentration range was found to be inconsistent for most of the drugs. Currently, no unified regulation exists for TDM charges in China, which is no more than \u00a5200 in general. Clinicians rely on pharmacists for professional guidance. Importantly, improvement in the interpretation of monitoring reports, proficiency testing, and cooperation with clinical departments may aid in improving the level of TDM service.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This survey objectively reflected the current status of TDM work in hospitals in China, and provided a strong reference base for devising strategies for improvement and effective execution of TDM work.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001060","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T16:05:13Z","timestamp":1678896313000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["A Survey of Therapeutic Drug Monitoring Status in China"],"prefix":"10.1097","volume":"45","author":[{"given":"Tao.","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"R1-20250603","first-page":"897","article-title":"The expert consensus on the standards of therapeutic drug monitoring","volume":"19","author":"Zhang","year":"2019"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.cgh.2019.09.041","article-title":"How, when, and for whom should we perform therapeutic drug monitoring?","volume":"18","author":"Vermeire","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R3-20250603","first-page":"741","article-title":"Development and prospect of therapeutic drug monitoring in China (In Chinese)","volume":"29","author":"Zhang","year":"2015","journal-title":"Chin J Pharmacol Toxicol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsps.2012.01.002","article-title":"A survey of therapeutic drug monitoring services in Malaysia","volume":"21","author":"Ab Rahman","year":"2013","journal-title":"Saudi Pharm J."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/ajhp\/57.23.2171","article-title":"ASHP national survey of pharmacy practice in acute care settings: monitoring, patient education, and wellness\u20142000","volume":"57","author":"Pedersen","year":"2000","journal-title":"Am J Health-System Pharm."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0031-1286281","article-title":"Therapeutic drug monitoring in Italian psychiatry","volume":"44","author":"Conca","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/FTD.0b013e318296a2ff","article-title":"Therapeutic drug monitoring of psychotropic drugs in China: a nationwide survey","volume":"35","author":"Guo","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/ajhp\/53.23.2840","article-title":"National survey of hospital-based pharmacokinetic services","volume":"53","author":"Murphy","year":"1996","journal-title":"Am J Health-System Pharm."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2147\/IDR.S208783","article-title":"A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea","volume":"12","author":"Choi","year":"2019","journal-title":"Infect Drug Resist."},{"key":"R10-20250603","first-page":"43","article-title":"Hospital accreditation and authentication at home and abroad","volume":"38","author":"Li-Ping","year":"2018","journal-title":"Chin Hosp Management"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12913-019-4443-0","article-title":"Inequality in geographical distribution of hospitals and hospital beds in densely populated metropolitan cities of Iran","volume":"19","author":"Chavehpour","year":"2019","journal-title":"BMC Health Serv Res."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijantimicag.2012.10.002","article-title":"\u03b2-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia","volume":"41","author":"Hayashi","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of \u03b2-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R14-20250603","first-page":"3178","article-title":"Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for","volume":"70","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"e020070","DOI":"10.1136\/bmjopen-2017-020070","article-title":"Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia","volume":"8","author":"Li","year":"2018","journal-title":"BMJ Open"},{"key":"R16-20250603","first-page":"61","article-title":"A review on the implementation of the three-level hierarchical medical system","volume":"10","author":"Li","year":"2019","journal-title":"J Tech Innovation"},{"key":"R17-20250603","first-page":"1","article-title":"System thinking and advice of hierarchical medical services","volume":"36","author":"Yang","year":"2016","journal-title":"Hosp Manag China"},{"key":"R18-20250603","first-page":"5","article-title":"A statewide survey of pharmacokinetic service provision in Georgia [J]","volume":"26","author":"Murphy","year":"1991","journal-title":"Hosp Pharm."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/clpt.1994.112","article-title":"How effective are pharmacologic laboratories in big hospitals?","volume":"56","author":"Cridland","year":"1994","journal-title":"Clin Pharmacol Ther."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00007691-199812000-00002","article-title":"Delivery of therapeutic drug monitoring services: survey of Australasian clinical pharmacology laboratories","volume":"20","author":"Morris","year":"1998","journal-title":"Ther Drug Monit."},{"key":"R21-20250603","first-page":"1222","article-title":"Concentration determination of voriconazole in human plasma by HPLC-MS\/MS","volume":"34","author":"Yang","year":"2018","journal-title":"Chin J Clin Pharmacol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.2174\/138161212803523699","article-title":"Therapeutic drug monitoring for antidepressant drug treatment","volume":"18","author":"Ostad Haji","year":"2012","journal-title":"Curr Pharm Des."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R26-20250603","first-page":"210","article-title":"Analysis of external quality assessment result of national clinical laboratory from 2017 to 2019","volume":"28","author":"Feng","year":"2021","journal-title":"Hosp Adm J Chin people\u2019s Liberation Army"},{"key":"R27-20250603","first-page":"144","article-title":"Customer satisfaction with external quality assessment activity organized by national center of clinical laboratory","volume":"31","author":"Zhi-Guo","year":"2016","journal-title":"J Mod Lab Med."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/17425255.2016.1162785","article-title":"Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis","volume":"12","author":"Zuur","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."}],"updated-by":[{"DOI":"10.1097\/ftd.0000000000001117","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000}}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:20:19Z","timestamp":1748971219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001060","relation":{"correction":[{"id-type":"doi","id":"10.1097\/FTD.0000000000001117","asserted-by":"object"}]},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"2021-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}